Intestinal Behçet disease (BD), which is an immune-mediated, chronic, inflammatory intestinal disease, can be difficult to treat, in part because the pathogenesis of intestinal BD is unclear. However, as data for using anti–tumor necrosis factor (anti-TNF) drugs have been accumulating in the treatment of inflammatory bowel disease (IBD), which has a similar clinical presentation, the potential to treat BD with these agents is under investigation.
Intestinal Behçet's Disease (BD), which is an immune-mediated, chronic, inflammatory intestinal disease, can be difficult to treat, in part because the pathogenesis of intestinal BD is unclear. However, as data for using anti—tumor necrosis factor (anti-TNF) drugs have been accumulating in the treatment of inflammatory bowel disease (IBD), which has a similar clinical presentation, the potential to treat BD with these agents is under investigation.
A recently published review, appearing in Gut and Liver, explains the current knowledge base concerning anti-TNF agents in intestinal BD.
Infliximab, say the authors, was first shown to be effective in treating patients with intestinal BD who were steroid-dependent in 2001. Patients in that study had healing of their ulcers within 10 days and sustained remission for 12 months. Another study showed that infliximab plus methotrexate led to improvement in as little as 2 weeks. The first phase 3 trial in patients with intestinal BD resulted in rates of complete response of 55%, 55%, and 60% at weeks 14, 30, and 54, respectively, and a second phase 3 trial is ongoing.
Adalimumab has fewer data available in intestinal BD; the first prospective, open-label, single-arm, phase 3 multicenter trial of adalimumab found that complete remission was achieved by 20% of patients at weeks 24 and 52. At weeks 52 and 100, 60% and 40% of patients, respectively, showed a clinical response. Combination of adalimumab and disease-modifying anti-rheumatic drugs (DMARDs) did not appear to be superior to monotherapy. A prospective, multicenter study lasting 50 weeks has been completed but not yet reported, and a phase 3 trial is currently recruiting.
Etanercept has not been the subject of a phase 3 study in intestinal BD, and questions remain as to whether it could prove useful in intestinal BD given its inefficacy in treating IBD. Etanercept has also demonstrated the ability to produce paradoxical IBD in patients undergoing treatment for idiopathic juvenile arthritis.
Golimumab, too, has very few data available in treating intestinal BD. A single retrospective study that assessed the long-term efficacy and safety of golimumab in this indication found that 17 patients with BD—6 of whom had intestinal BD—who received golimumab for poorly controlled disease and treatment failure of at least 1 other biologic agent improved after a mean treatment time of 5 weeks. Combination therapy with DMARDs resulted in better outcomes than did monotherapy.
Certolizumab pegol is the only pegylated anti-TNF agent approved by the FDA. This therapy also has limited data concerning its use in intestinal BD, but a study in 13 patients with BD, 5 of whom had intestinal involvement, resulted in 7 patients exhibiting a satisfactory response.
Because many patients with intestinal BD fail to respond adequately to conventional therapies, say the authors, and because anti-TNF therapy has thus far demonstrated favorable outcomes in this patient population, use of anti-TNF agents should be further studied to clarify the rationale underlying the outcomes of the small studies described in the review.
Reference
Park J, Cheon JH. Anti—tumor necrosis factor therapy in intestinal Bechet’s Disease. [Published online May 24, 2018.] Gut Liver. doi: 10.5009/gnl17462.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.